[1] Zheng M,Sun H,Tian Z.Natural killer cells in liver diseases. Front Med,2018,19(4):1-8. [2] Desantis CE,Lin CC,Mariotto AB,et al.Cancer treatment and survivorship statistics,2014. CA Cancer J Clin,2012,62(4):220-226. [3] Hiraoka A,Ishimaru Y,Kawasaki H,et al.Tumor markers AFP,AFP-L3,and DCP in hepatocellular carcinoma refractory to transcatheter arterial Chemoembolization. Oncology,2015,89(3):1-8. [4] Li B,Li B,Guo T,et al.Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein,α-fetoprotein-L3,des-γ-carboxy prothrombin,and Golgi protein 73. Oncotarget,2017,8(46):80521-80530. [5] Zeng MD,Li YM,Chen CW,et al.Guidelines for the diagnosis and treatment of alcoholic liver disease. J Dig Dis,2008,9(2):113-116. [6] 孔颖,蔺淑梅,王维娟, 等. 血清高尔基体蛋白73诊断原发性肝癌价值探讨. 实用肝脏病杂志,2013,16(4):341-343. [7] 肖潇,何羽童,房萌,等. 甲胎蛋白异质体在原发性肝癌临床诊断中的应用. 实用肝脏病杂志,2017,20(5):567-570. [8] Ghouri YA,Mian I,Rowe JH.Review of hepatocellular carcinoma:Epidemiology,etiology,and carcinogenesis. J Carcinog,2017,16(1):1-12. [9] Wang NY,Wang C,Li W,et al.Prognostic value of serum AFP,AFP-L3,and GP73 in monitoring short-term treatment response and recurrence of hepatocellular carcinoma after radiofrequency ablation. Asian Pac J Cancer Prev,2014,15(4):1539-1544. [10] Zhao J,Guo LY,Yang JM,et al.Sublingual vein parameters,AFP,AFP-L3,and GP73 in patients with hepatocellular carcinoma. Genet Mol Res,2015,14(2):7062-7067. [11] Marrero JA,Romano PR,Nikolaeva O,et al.GP73,a resident Golgi glycoprotein,is a novel serum marker for hepatocellular carcinoma. J Hepatol,2005,43(6):1007-1012. [12] Iftikhar R,Kladney RD,Havlioglu N,et al.Disease-and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol,2004,99(6):1087-1096. [13] Park SJ,Jang JY,Jeong SW,et al.Usefulness of AFP,AFP-L3,and PIVKA-II,and their combinations in diagnosing hepatocellular carcinoma. Medicine,2017,96(11):e5811. [14] Durazo FA,Blatt LM,Corey WG,et al.Des-gamma-carboxyprothrombin,alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis,cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol,2008,23(10):1541-1548. [15] Setsu T,Tsuchiya A,Watanabe T,et al.Early detection of hepatocellular carcinoma recurrence using the highly sensitive fucosylated fraction of alpha-fetoprotein. Case Rep Gastroenterol,2017,11(1):142-147. [16] Zuo D,Chen L,Liu X,et al.Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. Tumour Biol,2016,37(5):6539-6549. [17] Zhang N,Gu J,Yin L,et al.Incorporation of alpha-fetoprotein(AFP) into subclassification of BCLC C stage hepatocellular carcinoma according to a 5-year survival analysis based on the SEER database. Oncotarget,2016,7(49):81389-81401. [18] Junna Z,Gongde C,Jinying X,et al.Serum AFU,5'-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis. Open Med,2017,12(1):354-358. [19] Mossad NA,Mahmoud EH,Osman EA,et al.Evaluation of squamous cell carcinoma antigen-immunoglobulin M complex (SCCA-IGM) and alpha-L-fucosidase(AFU) as novel diagnostic biomarkers for hepatocellular carcinoma. Tumour Biol,2014,35(11):11559-11564. [20] Choi JY,Jung SW,Kim HY,et al.Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP. World J Gastroenterol,2013,19(3):339-346. |